NCT04206644Active, not recruiting
Systemic Sclerosis and Jak Inhibitors : Emphasis on Macrophages
Source: ClinicalTrials.gov · Last updated 12 Apr 2023
Brief summary (registry, in English)
The Sclero-JAK project aims to assess the impact of a JAK1/2 inhibitor (ruxolitinib) on activation states of monocytes-derived macrophages (MDM) from systemic sclerosis (SSc) patients
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 150 (actual)
- First submitted
- 18 Dec 2019
- Start date
- 21 Jan 2021
- Primary completion date
- 13 Jan 2023
- Lead sponsor
- Rennes University Hospital
- Diseases
- Systemic sclerosis (scleroderma)
- NCT number
- NCT04206644
What you commit to
- Study type: Observational
- Participants enrolled: 150
- From 21 Jan 2021 to the primary completion date, 13 Jan 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- patients unable to consent
- patients with anemia inferior to 7g/dL
Who the study is looking for
- patients with systemic sclerosis according to the ACR/EULAR 2013 classification criteria for systemic sclerosis or Patients with systemic lupus according to the ACR2019 classification criteria for systemic lupus
- with informed consent for participation to the study
Age in the registry: 18 years to 18 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Rennes University Hospital Coordinator of this site? Confirm its status | Rennes | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.